Pfizer Inc Stock Performance
| PFE Stock | USD 25.65 0.52 2.07% |
The company holds a Beta of 0.38, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pfizer's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pfizer is expected to be smaller as well. At this point, Pfizer Inc has a negative expected return of -0.15%. Please make sure to check Pfizer's kurtosis, and the relationship between the maximum drawdown and day median price , to decide if Pfizer Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 2.07 | Five Day Return 2.72 | Year To Date Return (13.72) | Ten Year Return (10.47) | All Time Return 5.9 K |
Forward Dividend Yield 0.0655 | Payout Ratio 0.6512 | Last Split Factor 1054:1000 | Forward Dividend Rate 1.68 | Dividend Date 2024-12-02 |
| Pfizer dividend paid on 3rd of September 2024 | 09/03/2024 |
1 | GW Henssler Associates Ltd. Makes New 289,000 Investment in Pfizer Inc. | 10/29/2024 |
2 | Opko health CEO Phillip Frost purchases 421,535 in stock | 11/08/2024 |
3 | Arvinas chief accounting officer David Loomis sells 10,300 in stock | 11/12/2024 |
4 | Vaccines makers close lower on reports RFK Jr may head HHS | 11/14/2024 |
5 | Acquisition by Albert Bourla of tradable shares of Pfizer subject to Rule 16b-3 | 11/15/2024 |
6 | Jim Cramer on Pfizer Inc. Still, Anything Good There, It Could Fly | 11/18/2024 |
7 | Hypocrite JoeScarborough blasted for ideological U-turns to chase success and social status sources | 11/19/2024 |
8 | Padres Pedal the Cause Is Now Curebound Cancer Challenge, Kicks Off with 1.1 Million Philanthropic Gift as Organization Doubles Down on Mission to End Cancer | 11/21/2024 |
9 | Joe Rogan and Josh Brolin rant about COVID-19 vaccine | 11/22/2024 |
| Begin Period Cash Flow | 468 M | |
| Total Cashflows From Investing Activities | -32.3 B |
Pfizer |
Pfizer Relative Risk vs. Return Landscape
If you would invest 2,848 in Pfizer Inc on August 26, 2024 and sell it today you would lose (283.00) from holding Pfizer Inc or give up 9.94% of portfolio value over 90 days. Pfizer Inc is generating negative expected returns assuming volatility of 1.3885% on return distribution over 90 days investment horizon. In other words, 12% of stocks are less volatile than Pfizer, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Pfizer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pfizer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pfizer Inc, and traders can use it to determine the average amount a Pfizer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.109
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PFE |
Estimated Market Risk
| 1.39 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pfizer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pfizer by adding Pfizer to a well-diversified portfolio.
Pfizer Fundamentals Growth
Pfizer Stock prices reflect investors' perceptions of the future prospects and financial health of Pfizer, and Pfizer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pfizer Stock performance.
| Return On Equity | 0.0454 | ||||
| Return On Asset | 0.0331 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 202.02 B | ||||
| Shares Outstanding | 5.67 B | ||||
| Price To Earning | 9.48 X | ||||
| Price To Book | 1.58 X | ||||
| Price To Sales | 2.45 X | ||||
| Revenue | 58.5 B | ||||
| Gross Profit | 66.23 B | ||||
| EBITDA | 9.56 B | ||||
| Net Income | 2.13 B | ||||
| Cash And Equivalents | 2.85 B | ||||
| Cash Per Share | 6.44 X | ||||
| Total Debt | 75.04 B | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 1.59 X | ||||
| Book Value Per Share | 16.29 X | ||||
| Cash Flow From Operations | 8.7 B | ||||
| Earnings Per Share | 0.75 X | ||||
| Market Capitalization | 145.36 B | ||||
| Total Asset | 226.5 B | ||||
| Retained Earnings | 118.35 B | ||||
| Working Capital | (4.46 B) | ||||
| Current Asset | 43.8 B | ||||
| Current Liabilities | 29.4 B | ||||
About Pfizer Performance
By analyzing Pfizer's fundamental ratios, stakeholders can gain valuable insights into Pfizer's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pfizer has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pfizer has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 125.27 | 119.01 | |
| Return On Tangible Assets | 0.02 | 0.02 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.02 | 0.02 |
Things to note about Pfizer Inc performance evaluation
Checking the ongoing alerts about Pfizer for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pfizer Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pfizer Inc generated a negative expected return over the last 90 days | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from newsweek.com: Joe Rogan and Josh Brolin rant about COVID-19 vaccine |
- Analyzing Pfizer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pfizer's stock is overvalued or undervalued compared to its peers.
- Examining Pfizer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pfizer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pfizer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pfizer's stock. These opinions can provide insight into Pfizer's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |